KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$0.51.

  • Moderna's EPS (Basic) fell 180000.0% to -$0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.07, marking a year-over-year decrease of 3889.85%. This contributed to the annual value of -$9.27 for FY2024, which is 2478.96% up from last year.
  • Per Moderna's latest filing, its EPS (Basic) stood at -$0.51 for Q3 2025, which was down 180000.0% from -$2.13 recorded in Q2 2025.
  • Over the past 5 years, Moderna's EPS (Basic) peaked at $12.06 during Q4 2021, and registered a low of -$9.53 during Q3 2023.
  • Its 5-year average for EPS (Basic) is $1.3, with a median of $0.2 in 2023.
  • As far as peak fluctuations go, Moderna's EPS (Basic) skyrocketed by 233548.39% in 2021, and later plummeted by 180000.0% in 2025.
  • Moderna's EPS (Basic) (Quarter) stood at $12.06 in 2021, then tumbled by 68.08% to $3.85 in 2022, then plummeted by 85.45% to $0.56 in 2023, then plummeted by 620.83% to -$2.92 in 2024, then skyrocketed by 82.51% to -$0.51 in 2025.
  • Its EPS (Basic) was -$0.51 in Q3 2025, compared to -$2.13 in Q2 2025 and -$2.52 in Q1 2025.